Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drugs industry.
multimmune GmbH's cancer theranostics programs have been supported by investment from a number of sources:
- Technology Investment Fund Bayern III GmbH & Co. KG
- S-Refit AG / Sobera Capital GmbH)
- Raabe Verögensverwaltungs GmbH
- SilverSky LifeSciences GmbH
- Private Investors
In 2020, multimmune GmbH entered into an exclusive licensing deal with ALPHAGENERON Pharmaceuticals Inc., Cambridge, USA. This will advance our NK cell therapy and associated Companion Diagnostic (CDx), as well as our other pipelines into more extensive clinical trials and commercialization.
“The potential for this NK cell therapy to treat a large range of aggressive cancers is a revolutionary breakthrough,” said Robert K. Brooks, JD, Chief Executive Officer of ALPHAGENERON Pharmaceuticals Inc.